Karen Rowland Yeo (Karen Rowland-Yeo)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 21

Top Topics

Diabetic Retinopathy

Molecular Dynamics

Small Cell Lung Cancer

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Karen Rowland Yeo, Eva Gil Bergland, Yuan Chen
Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future. Clinical pharmacology and therapeutics (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Karen Rowland Yeo, Eva Gil Berglund, Yuan Chen
Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future. Clinical pharmacology and therapeutics 116 (3) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Michael J Hanley, Karen Rowland Yeo, Meera Tugnait, Shinji Iwasaki, Narayana Narasimhan, Pingkuan Zhang, Karthik Venkatakrishnan, Neeraj Gupta
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Amita Pansari, Xian Pan, Lisa M Almond, Karen Rowland Yeo
A tutorial on physiologically based pharmacokinetic approaches in lactation research. CPT: pharmacometrics & systems pharmacology (2024)
Karen Rowland Yeo, David Wesche
PBPK modeling of ivermectin - considerations for the purpose of developing alternative routes to optimize its safety profile. CPT: pharmacometrics & systems pharmacology (2023)
Ian E Templeton, Karen Rowland Yeo, Hannah M Jones, Christopher J Endres, Ariel R Topletz-Erickson, Hao Sun, Anthony J Lee
Creation of novel sensitive probe substrate and moderate inhibitor models for a comprehensive prediction of CYP2C8 interactions for tucatinib. Clinical pharmacology and therapeutics (2023)
Xian Pan, Khaled Abduljalil, Lisa M Almond, Amita Pansari, Karen Rowland Yeo
Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example. CPT: pharmacometrics & systems pharmacology (2023)
Xian Pan, Karen Rowland Yeo
Physiologically based pharmacokinetic modelling to determine the impact of CYP2B6 genotype on efavirenz exposure in children, mothers and breastfeeding infants. Clinical pharmacology and therapeutics (2023)
Nada Abla, Eleanor Howgate, Karen Rowland Yeo, Maurice Dickins, Mackenzie C Bergagnini-Kolev, Kuan-Fu Chen, Savannah McFeely, Jennifer J Bonner, Laura G A Santos, Nathalie Gobeau, Howard Burt, Zoe Barter, Hannah M Jones, David Wesche, Susan A Charman, Jörg J Möhrle, Jeremy N Burrows, Lisa M Almond
Development and application of a PBPK modeling strategy to support antimalarial drug development. CPT: pharmacometrics & systems pharmacology (2023)
Ben G Small, Trevor N Johnson, Karen Rowland Yeo
Another Step Toward Qualification of Pediatric Physiologically Based Pharmacokinetic Models to Facilitate Inclusivity and Diversity in Pediatric Clinical Studies. Clinical pharmacology and therapeutics (2022)
Peter J Kilford, Kuan-Fu Chen, Kim Crewe, Iain Gardner, Oliver Hatley, Alice Ban Ke, Sibylle Neuhoff, Mian Zhang, Karen Rowland Yeo
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator. CPT: pharmacometrics & systems pharmacology 11 (7) (2022)
Xian Pan, Karen Rowland Yeo
Addressing drug safety of maternal therapy during breastfeeding using physiologically-based pharmacokinetic modeling. CPT: pharmacometrics & systems pharmacology 11 (5) (2022)
Trevor N Johnson, Ben G Small, Karen Rowland Yeo
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT: pharmacometrics & systems pharmacology 11 (3) (2022)
Trevor N Johnson, Ben G Small, Eva Gil Berglund, Karen Rowland Yeo
A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development. CPT: pharmacometrics & systems pharmacology 10 (9) (2021)
Karen Rowland Yeo, Karthik Venkatakrishnan
Physiologically-Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study. Clinical pharmacology and therapeutics 109 (1) (2020)